STOCK TITAN
  1. Home
  2. News
  3. MBRX

Moleculin Biotech Inc - MBRX STOCK NEWS

Welcome to our dedicated news page for Moleculin Biotech (Ticker: MBRX), a resource for investors and traders seeking the latest updates and insights on Moleculin Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Moleculin Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Moleculin Biotech's position in the market.

News
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
Rhea-AI Summary
Moleculin Biotech, Inc. receives Orphan Drug Designation from the European Medicines Agency (EMA) for Annamycin, a next-generation anthracycline, for the treatment of Acute Myeloid Leukemia (AML). Annamycin shows promising clinical efficacy in AML with a preliminary complete response rate of 60% in 2nd line subjects in a European clinical trial. The drug demonstrates lower toxicity than traditional therapies and is advancing towards a pivotal AML study in 2024. The Orphan Drug Designation provides commercial exclusivity and regulatory benefits for Moleculin's innovative cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
Rhea-AI Summary
Moleculin Biotech, Inc. announces positive preclinical data on Annamycin, a potent anthracycline with non-cardiotoxic properties, presented at AACR Annual Meeting. Annamycin shows high potency against topoisomerase II-alpha and II-beta, while remaining safe for cardiomyocytes. The company's recent patent issuance enables expansion into patient populations with unmet needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
none
-
News
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
Rhea-AI Summary
Moleculin Biotech, Inc. (MBRX) to present at the MedInvest Biotech & Pharma Investor Conference on April 4th, 2024. The company's President and CEO, Walter Klemp, will discuss their drug candidates targeting tumors and viruses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.68%
Tags
conferences
News
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
Rhea-AI Summary
Moleculin Biotech, Inc. (MBRX) will present at the Virtual Investor Lunch Break, featuring Chairman and CEO Walter Klemp discussing the company's drug candidates targeting tumors and viruses. The event will take place on March 28th, with a live webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.38%
Tags
conferences
-
News
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
Rhea-AI Summary
Moleculin Biotech, Inc. receives a patent for a next-generation anthracycline with composition of matter protection until 2040, showcasing promising results in treating AML patients and soft tissue sarcoma lung metastases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.38%
Tags
none
-
News
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
Rhea-AI Summary
Moleculin Biotech, Inc. announces positive results for Annamycin in combination with Cytarabine (AnnAraC) in 2nd line AML subjects, achieving a CRc rate of 60% with a potential to fill a significant unmet need. The company reports no signs of cardiotoxicity in all 82 Annamycin subjects and plans to advance towards a pivotal AML study in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.97%
Tags
clinical trial
News
Moleculin Reports Full Year 2023 Financial Results
Rhea-AI Summary
Moleculin Biotech, Inc. reports positive clinical data for Annamycin, plans pivotal study for AML. Financial results show increased R&D expenses but decreased G&A expenses. The company closed a direct offering and private placement, extending cash runway into Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.97%
Tags
earnings
-
News
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
Rhea-AI Summary
Moleculin Biotech, Inc. announces the discussion of stratification of Company's 2nd line data of Annamycin for acute myeloid leukemia (AML) therapy. They will provide guidance for the clinical development strategy to advance Annamycin into a potential AML pivotal registration study. The company will report its financial results for the year ended December 31, 2023, on March 22, 2024, and host a conference call on March 25, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.7%
Tags
conferences earnings
-
News
Moleculin Announces Reverse Stock Split
Rhea-AI Summary
Moleculin Biotech, Inc. announces a 1-for-15 reverse stock split to regain compliance with Nasdaq listing requirements. The split will consolidate every fifteen shares into one, reducing outstanding shares from 33.4 million to 2.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.7%
Tags
stock split
News
Moleculin to Present at the 36th Annual ROTH Conference
Rhea-AI Summary
Moleculin Biotech, Inc. (MBRX) will have a fireside chat at the 36th Annual ROTH Conference on March 18th. Jonathan Foster, the CFO, will participate, showcasing the company's drug candidates for tumors and viruses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.22%
Tags
conferences
Stock MBRX logo
Moleculin Biotech Inc

Nasdaq:MBRX

MBRX Rankings

#5350 Ranked by Market Cap
#4719 Ranked by Stock Gains
N/A Ranked by Dividends

MBRX Stock Data

10.31M
1.93M
4.65%
15.52%
2.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Houston

About MBRX

moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.